ReviewHepatobiliary surgery and nutrition2017
Epidemiology and risk factors: intrahepatic cholangiocarcinoma.
Review in Hepatobiliary surgery and nutrition, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association between gallstones and the risk of biliary tract cancer: a systematic review and meta-analysis.Epidemiology and health · 2021Pooled it
- Single-cell multi-omics analysis reveals drivers of intrahepatic cholangiocarcinoma metastasis.BMC cancer · 2025Article
- Intrahepatic cholangiocarcinoma mortality in the USA, 1999-2020: a 21-year population-based analysis.Cancer causes & control : CCC · 2025Article
- Advances in Multi-Omics Research on Biomarkers of Intrahepatic Cholangiocarcinoma.Current issues in molecular biology · 2025Review
- Construction and validation of a novel prognostic model for postoperative patients with stage I intrahepatic cholangiocarcinoma: a population-based study.Langenbeck's archives of surgery · 2025Article
- Characteristics of "Very Early" Intrahepatic Cholangiocarcinoma Undergoing Liver Resection and Its Relationship With Carbohydrate Antigen 19-9.Journal of surgical oncology · 2025Article
- Genetic evidence for the causal influence of inflammatory factors on intrahepatic cholangiocarcinoma risk.World journal of gastrointestinal oncology · 2025Article
- Single cell RNA sequencing to identify an Immunogenic cell death related prognostic signature in intrahepatic cholangiocarcinoma.Scientific reports · 2025Article
- Three-dimensional genome architecture in intrahepatic cholangiocarcinoma.Cellular oncology (Dordrecht, Netherlands) · 2025Article
- Temporal trends and patterns for early- and late-onset adult liver cancer incidence vary by race/ethnicity, subsite, and histologic type in the United States from 2000 to 2019.Cancer causes & control : CCC · 2025Article
- Impact of tobacco exposure on global deaths of digestive diseases: Findings from 1990-2021 and projected trends to 2042.Tobacco induced diseases · 2025Article
- Imaging cholangiocarcinoma: CT and MRI techniques.Abdominal radiology (New York) · 2025Review
- A case report of a rare intrahepatic cholangiocarcinoma with rectal metastasis.Frontiers in oncology · 2025Article
- CLDN18.2: a potential nanotherapeutic target for cholangiocarcinoma.Frontiers in pharmacology · 2025Review
- Management of Localized Intrahepatic Cholangiocarcinoma: What Exactly is the 'Evidence'?Annals of surgical oncology · 2024Article
- HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironment.Journal of cancer research and clinical oncology · 2024Article
- Unveil Intrahepatic Cholangiocarcinoma Heterogeneity through the Lens of Omics and Multi-Omics Approaches.Cancers · 2024Review
- Dual Inhibition of PI3 Kinase and MAP Kinase Signaling Pathways in Intrahepatic Cholangiocellular Carcinoma Cell Lines Leads to Proliferation Arrest but Not Apoptosis.Current issues in molecular biology · 2024Article
- Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker.Clinical and translational medicine · 2024Article
- Efficacy of dual checkpoint inhibitors in a patient with a mixed hepatocellular cholangiocarcinoma.BMJ case reports · 2024Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intrahepatic cholangiocarcinoma (ICC) is a rare entity with a distinct clinical course and epidemiology from hilar and extrahepatic cholangiocarcinoma. ICC makes up 8-10% of cholangiocarcinomas and 10-20% of all primary liver tumors. There remains a considerable amount of geographic variation in the incidence of ICC worldwide; however, the overall incidence of this malignancy appears to be rising. Several risk factors have been identified, such as infectious causes (liver flukes, viral hepatitis), biliary tract disease [primary sclerosing cholangitis (PSC), hepaticolithiasis, biliary cystic diseases], metabolic syndrome, lifestyle choices (alcohol abuse, tobacco use), and cirrhosis. Despite this, a substantial number of ICC patients do not have any identifiable risk factors, underlining the need for further work into the pathogenesis of this malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.